Business Context and Reporting Period
This Form 8-K Current Report was filed by Dare Bioscience, Inc. on December 7, 2021. The filing reports a significant regulatory milestone: the U.S. Food and Drug Administration (FDA) approved the New Drug Application for the company's product DARE-BV1, marketed as XACIATO (clindamycin phosphate vaginal gel, 2%).
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on the regulatory approval event and forward-looking commercialization plans.
Material Changes
- Regulatory Approval: FDA approval granted for XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.
- Product Specifications: XACIATO is a clear, colorless, viscous gel delivered via a single-dose user-filled disposable applicator containing 5 g of gel with 100 mg of clindamycin.
- Market Exclusivity: Due to Qualified Infectious Disease Product (QIDP) designation, the product is expected to receive a five-year extension to the standard three years of market exclusivity.
Guidance, Outlook, and Risks
Outlook and Strategy: The company is conducting strategic partnering discussions to support a robust market introduction of XACIATO in the United States during 2022. A conference call regarding partnership and market strategy is scheduled once a definitive agreement is finalized.
Risks and Contingencies: Forward-looking statements regarding the 2022 launch and partnership finalization are subject to risks, including uncertainties in commercialization, potential delays in timelines, and the failure to establish third-party partnerships. The company disclaims any obligation to update these statements.
Investor Verification Checklist
- Confirm the finalization and terms of the strategic partnership agreement for XACIATO commercialization.
- Verify the specific timeline for the U.S. market launch in 2022.
- Review the company's cash position in recent 10-K or 10-Q filings to assess runway for commercialization efforts.
- Monitor for the scheduled conference call to discuss partnership details.